Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

Frontiers in Aging Neuroscience

Volumn 6, Issue JUL, 2014, Pages

  Ardah, Mustafa Taleb ^a   Paleologou, Katerina E ^b   Lv, Guohua ^c   Khair, Salema Begum Abul ^a   Kendi, Abdullah KazimAl ^a   Minhas, Saeed Tarek ^a   Al Tel, Taleb H ^d   Al Hayani, Abdulmonem A ^e   Haque, Mohammed Emdadul ^a   Eliezer, David ^c   El Agnaf, Omar M A ^a,e  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF SHARJAH   (United Arab Emirates)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Aggregation; Amyloid fibrils; Drug discovery; Gallic acid; Parkinson's disease; Synuclein

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; 3 HYDROXYBENZOIC ACID; 3,4,5 TRIHFLUOROBENZOIC ACID; 3,4,5 TRIMETHOXYBENZOIC ACID; 4 HYDROXYBENZOIC ACID; ALPHA RESORCYLIC ACID; ALPHA SYNUCLEIN; AMYLOID; ANISIC ACID; BENZOIC ACID DERIVATIVE; BETA RESORCYLIC ACID; GALLIC ACID; GAMMA RESORCYLIC ACID; GENTISIC ACID; HYDROXYBENZOIC ACID DERIVATIVE; PHENOL DERIVATIVE; PHLOROGLUCINOLCARBOXYLIC ACID; PROTEIN INHIBITOR; PROTOCATECHUIC ACID; SALICYLIC ACID; UNCLASSIFIED DRUG; BENZOIC ACID;

ABSORPTION; AMINO ACID SEQUENCE; ARTICLE; BINDING ASSAY; CELL DEATH; CELL VIABILITY; CELL VIABILITY ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR WEIGHT; MOLECULE; MTT ASSAY; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NEUROBLASTOMA CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; BETA SHEET; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DRUG PROTEIN BINDING; HUMAN TISSUE; IN VITRO STUDY; NEUROPROTECTION; PROTEIN AGGREGATION;

EID: 84904637112     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00197     Document Type: Article

References (85)

1. ALLSOP, D., SWANSON, L., MOORE, S., DAVIES, Y., YORK, A., EL-AGNAF, O. M. & SOUTAR, I. 2001 Fluorescence anisotropy: a method for early detection of Alzheimer beta-peptide (Abeta) aggregation. Biochem Biophys Res Commun, 285, 58-63
2. APPEL-CRESSWELL, S., VILARINO-GUELL, C., ENCARNACION, M., SHERMAN, H., YU, I., SHAH, B., WEIR, D., THOMPSON, C., SZU-TU, C., TRINH, J., AASLY, J. O., RAJPUT, A., RAJPUT, A. H., JON STOESSL, A. & FARRER, M. J. 2013. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease Mov Disord, 28, 811-3
3. ARGYRIOU, A., DERMENTZAKI, G., PAPASILEKAS, T., MORAITOU, M., STAMBOULIS, E., VEKRELLIS, K., MICHELAKAKIS, H. & STEFANIS, L. 2012. Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci Lett, 528, 205-9
4. BAN, J. Y., NGUYEN, H. T., LEE, H. J., CHO, S. O., JU, H. S., KIM, J. Y., BAE, K., SONG, K. S. & SEONG, Y. H. 2008 Neuroprotective properties of gallic acid from Sanguisorbae radix on amyloid beta protein (25--35)-induced toxicity in cultured rat cortical neurons. Biol Pharm Bull, 31, 149-53
5. BASTIANETTO, S., YAO, Z. X., PAPADOPOULOS, V. & QUIRION, R. 2006. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci, 23, 55-64
6. BREYDO, L., WU, J. W. & UVERSKY, V. N. 2012. Α-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta, 1822, 261-85
7. BUSSELL, R. & ELIEZER, D. 2003. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol, 329, 763-78
8. CAMILLERI, A. & VASSALLO, N. 2014. The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease. CNS Neurosci Ther
9. CANNON, J. R., GEGHMAN, K. D., TAPIAS, V., SEW, T., DAIL, M. K., LI, C. & GREENAMYRE, J. T. 2013 Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol, 240, 44-56
10. CARUANA, M., HÖGEN, T., LEVIN, J., HILLMER, A., GIESE, A. & VASSALLO, N. 2011. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett, 585, 1113-20
11. COLLA, E., JENSEN, P. H., PLETNIKOVA, O., TRONCOSO, J. C., GLABE, C. & LEE, M. K. 2012. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci, 32, 3301-5
12. CONWAY, K. A., HARPER, J. D. & LANSBURY, P. T. 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-63
13. DI GIOVANNI, S., ELEUTERI, S., PALEOLOGOU, K. E., YIN, G., ZWECKSTETTER, M., CARRUPT, P. A. & LASHUEL, H. A. 2010. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem, 285, 14941-54
14. DORVAL, V. & FRASER, P. E. 2007. SUMO on the road to neurodegeneration. Biochim Biophys Acta, 1773, 694-706
15. EBRAHIMI, A. & SCHLUESENER, H. 2012. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res Rev, 11, 329-45
16. EHRNHOEFER, D. E., BIESCHKE, J., BOEDDRICH, A., HERBST, M., MASINO, L., LURZ, R., ENGEMANN, S., PASTORE, A. & WANKER, E. E. 2008. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol, 15, 558-66
17. EL-AGNAF, O. M., JAKES, R., CURRAN, M. D. & WALLACE, A. 1998. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett, 440, 67-70
18. EL-AGNAF, O. M., NAGALA, S., PATEL, B. P. & AUSTEN, B. M. 2001. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol, 310, 157-68
19. EL-AGNAF, O. M., SALEM, S. A., PALEOLOGOU, K. E., CURRAN, M. D., GIBSON, M. J., COURT, J. A., SCHLOSSMACHER, M. G. & ALLSOP, D. 2006. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. United States
20. ELIEZER, D., KUTLUAY, E., BUSSELL, R. & BROWNE, G. 2001. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol, 307, 1061-73
21. FAUVET, B., MBEFO, M. K., FARES, M. B., DESOBRY, C., MICHAEL, S., ARDAH, M. T., TSIKA, E., COUNE, P., PRUDENT, M., LION, N., ELIEZER, D., MOORE, D. J., SCHNEIDER, B., AEBISCHER, P., EL-AGNAF, O. M., MASLIAH, E. & LASHUEL, H. A. 2012. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem, 287, 15345-64
22. FEANY, M. B. & BENDER, W. W. 2000. A Drosophila model of Parkinson's disease. Nature, 404, 394-8
23. FINK, A. L. 2006. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res, 39, 628-34
24. GIASSON, B. I., URYU, K., TROJANOWSKI, J. Q. & LEE, V. M. 1999. Mutant and wild type human alpha synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem, 274, 7619-22
25. GREENBAUM, E. A., GRAVES, C. L., MISHIZEN-EBERZ, A. J., LUPOLI, M. A., LYNCH, D. R., ENGLANDER, S. W., AXELSEN, P. H. & GIASSON, B. I. 2005. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem, 280, 7800-7
26. HAMLEY, I. W. 2012. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization Chem Rev, 112, 5147-92
27. HARPER, J. D. & LANSBURY, P. T. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem, 66, 385-407
28. HARPER, J. D., WONG, S. S., LIEBER, C. M. & LANSBURY, P. T. 1999. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry, 38, 8972-80
29. HASHIMOTO, M., HSU, L. J., SISK, A., XIA, Y., TAKEDA, A., SUNDSMO, M. & MASLIAH, E. 1998. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res, 799, 301-6
30. HO, H. H., CHANG, C. S., HO, W. C., LIAO, S. Y., LIN, W. L. & WANG, C. J. 2013. Gallic acid inhibits gastric cancer cells metastasis and invasive growth via increased expression of RhoB, downregulation of AKT/small GTPase signals and inhibition of NF-κB activity. Toxicol Appl Pharmacol, 266, 76-85
31. HO, J. H. & HONG, C. Y. 2011. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci, 18, 30
32. HONG, S. Y., JEONG, W. S. & JUN, M. 2012. Protective effects of the key compounds isolated from Corni fructus against β-amyloid-induced neurotoxicity in PC12 cells. Molecules, 17, 10831-45
33. IBÁÑEZ, P., BONNET, A. M., DÉBARGES, B., LOHMANN, E., TISON, F., POLLAK, P., AGID, Y., DÜRR, A. & BRICE, A. 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease Lancet, 364, 1169-71
34. IMAI, Y., VENDEROVA, K., PARK, D. S., CAI, H. & SCHMIDT, E. 2011. Animal models of Parkinson's disease Parkinsons Dis, 2011, 364328
35. IRVINE, G. B., EL-AGNAF, O. M., SHANKAR, G. M. & WALSH, D. M. 2008. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med, 14, 451-64
36. JARRETT, J. T. & LANSBURY, P. T. 1992. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB Biochemistry, 31, 12345-52
37. JARRETT, J. T. & LANSBURY, P. T. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 73, 1055-8
38. JUNN, E. & MOURADIAN, M. M. 2002. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett, 320, 146-50
39. KAHLE, P. J. 2008. alpha-Synucleinopathy models and human neuropathology: similarities and differences Acta Neuropathol, 115, 87-95
40. KAHLE, P. J., NEUMANN, M., OZMEN, L., MÜLLER, V., ODOY, S., OKAMOTO, N., JACOBSEN, H., IWATSUBO, T., TROJANOWSKI, J. Q., TAKAHASHI, H., WAKABAYASHI, K., BOGDANOVIC, N., RIEDERER, P., KRETZSCHMAR, H. A. & HAASS, C. 2001. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol, 159, 2215-25
41. KAYLOR, J., BODNER, N., EDRIDGE, S., YAMIN, G., HONG, D. P. & FINK, A. L. 2005. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha synuclein. J Mol Biol. England
42. KIELY, A. P., ASI, Y. T., KARA, E., LIMOUSIN, P., LING, H., LEWIS, P., PROUKAKIS, C., QUINN, N., LEES, A. J., HARDY, J., REVESZ, T., HOULDEN, H. & HOLTON, J. L. 2013. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol, 125, 753-69
43. KIM, D. H., PARK, S. J., KIM, J. M., JEON, S. J., CHO, Y. W., SON, K. H., LEE, H. J., MOON, J. H., CHEONG, J. H., KO, K. H. & RYU, J. H. 2011. Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B. Neuropharmacology, 61, 1432-40
44. KIM, Y. J. 2007. Antimelanogenic and antioxidant properties of gallic acid. Biol Pharm Bull, 30, 1052-5
45. KREIS, W., KAPLAN, M. H., FREEMAN, J., SUN, D. K. & SARIN, P. S. 1990. Inhibition of HIV replication by Hyssop officinalis extracts. Antiviral Res, 14, 323-37
46. KROES, B. H., VAN DEN BERG, A. J., QUARLES VAN UFFORD, H. C., VAN DIJK, H. & LABADIE, R. P. 1992. Anti inflammatory activity of gallic acid. Planta Med, 58, 499-504
47. KRÜGER, R., KUHN, W., MÜLLER, T., WOITALLA, D., GRAEBER, M., KÖSEL, S., PRZUNTEK, H., EPPLEN, J. T., SCHÖLS, L. & RIESS, O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18, 106-8
48. LEUNER, K., HAUPTMANN, S., ABDEL-KADER, R., SCHERPING, I., KEIL, U., STROSZNAJDER, J. B., ECKERT, A. & MÜLLER, W. E. 2007. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal, 9, 1659-75
49. LEVINE, H., LAMPE, L., ABDELMOTI, L. & AUGELLI-SZAFRAN, C. E. 2012. Dihydroxybenzoic acid isomers differentially dissociate soluble biotinyl-Aβ(1-42) oligomers. Biochemistry, 51, 307-15
50. LEVY-SAKIN, M., SHREBERK, M., DANIEL, Y. & GAZIT, E. 2009. Targeting insulin amyloid assembly by small aromatic molecules: toward rational design of aggregation inhibitors. Islets, 1, 210-5
51. LIU, K. C., HO, H. C., HUANG, A. C., JI, B. C., LIN, H. Y., CHUEH, F. S., YANG, J. S., LU, C. C., CHIANG, J. H., MENG, M. & CHUNG, J. G. 2011. Gallic acid provokes DNA damage and suppresses DNA repair gene expression in human prostate cancer PC-3 cells. Environ Toxicol
52. LUK, K. C., KEHM, V., CARROLL, J., ZHANG, B., O'BRIEN, P., TROJANOWSKI, J. Q. & LEE, V. M. 2012 Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338, 949-53
53. MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., MALLORY, M., HASHIMOTO, M., TAKEDA, A., SAGARA, Y., SISK, A. & MUCKE, L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265-9
54. MASUDA, M., SUZUKI, N., TANIGUCHI, S., OIKAWA, T., NONAKA, T., IWATSUBO, T., HISANAGA, S., GOEDERT, M. & HASEGAWA, M. 2006. Small molecule inhibitors of alpha-synuclein filament assembly Biochemistry, 45, 6085-94
55. MOSMANN, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63
56. ONO, K. & YAMADA, M. 2006. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem, 97, 105-15
57. PEREZ, R. G., WAYMIRE, J. C., LIN, E., LIU, J. J., GUO, F. & ZIGMOND, M. J. 2002. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci, 22, 3090-9
58. PERIER, C. & VILA, M. 2012. Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med, 2, a009332
59. POLYMEROPOULOS, M. H., LAVEDAN, C., LEROY, E., IDE, S. E., DEHEJIA, A., DUTRA, A., PIKE, B., ROOT, H., RUBENSTEIN, J., BOYER, R., STENROOS, E. S., CHANDRASEKHARAPPA, S., ATHANASSIADOU, A., PAPAPETROPOULOS, T., JOHNSON, W. G., LAZZARINI, A. M., DUVOISIN, R. C., DI IORIO, G., GOLBE, L I. & NUSSBAUM, R. L. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-7
60. PORAT, Y., ABRAMOWITZ, A. & GAZIT, E. 2006. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des, 67, 27-37
61. REINKE, A. A. & GESTWICKI, J. E. 2007. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des, 70, 206-15
62. SAMERI, M. J., SARKAKI, A., FARBOOD, Y. & MANSOURI, S. M. 2011. Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease. Pak J Biol Sci, 14, 1109-16
63. SCHMITT, K., GRIMM, A., KAZMIERCZAK, A., STROSZNAJDER, J. B., GÖTZ, J. & ECKERT, A. 2012. Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio. Antioxid Redox Signal, 16, 1456-66
64. SEIDLER, A., HELLENBRAND, W., ROBRA, B. P., VIEREGGE, P., NISCHAN, P., JOERG, J., OERTEL, W. H., ULM, G & SCHNEIDER, E. 1996. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology, 46, 1275-84
65. SERPELL, L. C., BERRIMAN, J., JAKES, R., GOEDERT, M. & CROWTHER, R. A. 2000a. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A, 97, 4897-902
66. SERPELL, L. C., BERRIMAN, J., JAKES, R., GOEDERT, M. & CROWTHER, R. A. 2000b. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A, 97, 4897-902
67. SINGLETON, A. B., FARRER, M., JOHNSON, J., SINGLETON, A., HAGUE, S., KACHERGUS, J., HULIHAN, M., PEURALINNA, T., DUTRA, A., NUSSBAUM, R., LINCOLN, S., CRAWLEY, A., HANSON, M., MARAGANORE, D., ADLER, C., COOKSON, M. R., MUENTER, M., BAPTISTA, M., MILLER, D., BLANCATO, J., HARDY, J. & GWINN-HARDY, K. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841
68. SPILLANTINI, M. G. & GOEDERT, M. 2000. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci, 920, 16-27
69. SPILLANTINI, M. G., SCHMIDT, M. L., LEE, V. M., TROJANOWSKI, J. Q., JAKES, R. & GOEDERT, M. 1997. Alpha synsuclein in Lewy bodies. Nature, 388, 839-40
70. STEFANIS, L. 2012. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med, 2, a009399
71. TANIGUCHI, S., SUZUKI, N., MASUDA, M., HISANAGA, S., IWATSUBO, T., GOEDERT, M. & HASEGAWA, M 2005. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem, 280, 7614-23
72. TAYLOR, J. P., HARDY, J. & FISCHBECK, K. H. 2002. Toxic proteins in neurodegenerative disease. Science, 296, 1991-5
73. TROJANOWSKI, J. Q. & LEE, V. M. 2003. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci, 991, 107-10
74. UVERSKY, V. N. 2008. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci, 9, 507-40
75. VEKRELLIS, K., XILOURI, M., EMMANOUILIDOU, E., RIDEOUT, H. J. & STEFANIS, L. 2011. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol, 10, 1015-25
76. VELDMAN, B. A., WIJN, A. M., KNOERS, N., PRAAMSTRA, P. & HORSTINK, M. W. 1998. Genetic and environmental risk factors in Parkinson's disease. Clin Neurol Neurosurg, 100, 15-26
77. VENDRUSCOLO, M., PACI, E., DOBSON, C. M. & KARPLUS, M. 2001. Three key residues form a critical contact network in a protein folding transition state. Nature, 409, 641-5
78. VOLPICELLI-DALEY, L. A., LUK, K. C., PATEL, T. P., TANIK, S. A., RIDDLE, D. M., STIEBER, A., MEANEY, D. F., TROJANOWSKI, J. Q. & LEE, V. M. 2011. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71
79. WAGNER, J., RYAZANOV, S., LEONOV, A., LEVIN, J., SHI, S., SCHMIDT, F., PRIX, C., PAN-MONTOJO, F., BERTSCH, U., MITTEREGGER-KRETZSCHMAR, G., GEISSEN, M., EIDEN, M., LEIDEL, F., HIRSCHBERGER, T., DEEG, A. A., KRAUTH, J. J., ZINTH, W., TAVAN, P., PILGER, J., ZWECKSTETTER, M., FRANK, T., BÄHR, M., WEISHAUPT, J. H., UHR, M., URLAUB, H., TEICHMANN, U., SAMWER, M., BÖTZEL, K., GROSCHUP, M., KRETZSCHMAR, H., GRIESINGER, C. & GIESE, A. 2013. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease Acta Neuropathol, 125, 795-813
80. WALSH, D. M., KLYUBIN, I., FADEEVA, J. V., CULLEN, W. K., ANWYL, R., WOLFE, M. S., ROWAN, M. J. & SELKOE, D. J. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535-9
81. WOOD, N. 1997. Genes and parkinsonism. J Neurol Neurosurg Psychiatry, 62, 305-9
82. YANG, C. S., CHUNG, J. Y., YANG, G. Y., LI, C., MENG, X. & LEE, M. J. 2000. Mechanisms of inhibition of carcinogenesis by tea. Biofactors, 13, 73-9
83. YANG, F., LIM, G. P., BEGUM, A. N., UBEDA, O. J., SIMMONS, M. R., AMBEGAOKAR, S. S., CHEN, P. P., KAYED, R., GLABE, C. G., FRAUTSCHY, S. A. & COLE, G. M. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem, 280, 5892-901
84. ZARRANZ, J. J., ALEGRE, J., GÓMEZ-ESTEBAN, J. C., LEZCANO, E., ROS, R., AMPUERO, I., VIDAL, L., HOENICKA, J., RODRIGUEZ, O., ATARÉS, B., LLORENS, V., GOMEZ TORTOSA, E., DEL SER, T., MUÑOZ, D. G. & DE YEBENES, J. G. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 55, 164-73
85. ZHU, M., RAJAMANI, S., KAYLOR, J., HAN, S., ZHOU, F. & FINK, A. L. 2004. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem, 279, 26846-57